加拿大全国早期关节炎队列八年间对类风湿关节炎系统层面绩效指标保持高依从性
该研究评估加拿大早期关节炎队列(2007-2015)中符合1987或2010年ACR/EULAR标准、症状持续时间小于1年且入组后随访至少1年的1763例早期类风湿关节炎患者对3项系统层面绩效指标的依从性。结果显示年度随访比例从100%降至91%,42%患者无超过12个月的随访间隔,64%无超过14个月的间隔,DMARD治疗比例保持在95-87%,75%在诊断后14天内启动DMARD,中位启动时间为1天。结论认为该队列在遵循方案的情况下对系统层面绩效指标有高依从性,随访时间延长后绩效略有下降。
要点
- 年度随访比例从100%降至91%,42%患者无超过12个月的随访间隔。
- DMARD治疗比例保持在95-87%,75%在诊断后14天内启动。
- 中位DMARD启动时间为1天,90百分位为93天。
核心结论
- 该早期类风湿关节炎队列在遵循方案的情况下对系统层面绩效指标有高依从性,随访时间延长后绩效略有下降,研究结果可用于绩效指标基准设定。
研究设计与样本
- 研究纳入加拿大早期关节炎队列(2007-2015)中符合1987或2010年ACR/EULAR标准、症状持续时间小于1年且入组后随访至少1年的患者,共1763例早期类风湿关节炎患者,按入组年份分层评估绩效指标的时间变化。
主要发现
- 8年间年度随访比例从100%降至91%,42%患者无超过12个月的随访间隔,64%患者无超过14个月的随访间隔。
- DMARD治疗比例保持在95-87%,75%的患者在诊断后14天内接受DMARD,中位启动时间为1天(90百分位93天)。
关键数值与推荐
- 评估的3项系统层面绩效指标为:年度随访比例及超过12或14个月的随访间隔数、DMARD治疗比例、从诊断到启动DMARD的天数。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess adherence to 3 system-level performance measures in a national early rheumatoid arthritis (RA) cohort. METHODS: Patients enrolled in the Canadian Early Arthritis Cohort (2007-2015) who met 1987 or 2010 American College of Rheumatology/European League Against Rheumatism criteria with <1 year of symptom duration and ≥1 year of followup after enrollment were included. Performance measures assessed were the percentage of RA patients seen in yearly followup, and the number of gaps between visits of >12 or >14 months, the percentage of RA patients treated with a disease-modifying antirheumatic drug (DMARD), and days from RA diagnosis to initiation of a DMARD. Results are shown stratified by enrollment year to assess for temporal changes in performance. RESULTS: A total of 1,763 early RA patients were included (mean age 54 years, 73% female, and 82% white). At enrollment, mean ± SD disease duration was 6 ± 3 months, and Disease Activity Score in 28 joints was 5.1 ± 1.5. Over 8 years, the proportion of patients seen in annual followup declined from 100% to 91%. Over followup, 42% of patients had 0 gaps in care of >12 months, and 64% had 0 gaps >14 months. The percentage of DMARD-treated early RA patients was and remained high (95-87%), and the percentage receiving DMARDs within 14 days of diagnosis was 75%. Median time-to-DMARD therapy was 1 day, indicating DMARDs were initiated at diagnosis (90th percentile 93 days). CONCLUSION: There was evidence of high adherence to system-level performance measures in this early RA cohort following a protocol. Small declines in performance were noted with increasing length of patient followup. Our findings are useful for performance measure benchmarking.
引用
- Barber CEH, Schieir O, Lacaille D, et al. High Adherence to System-Level Performance Measures for Rheumatoid Arthritis in a National Early Arthritis Cohort Over Eight Years. Arthritis Care Res (Hoboken). 2018. PMID: 29450976. doi:10.1002/acr.23439
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。